spacer
home > pmps > summer 2007 > the challenge of biotechnology
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Challenge of Biotechnology

Helmut Sommer of Christ Water Technology Group examines the treatment of critical waste water in the pharmaceutical industry

Today, biotechnology plays a major role in the pharmaceutical industry. Many products, especially vaccines and therapeutical substances, are manufactured with the aid of biotechnological methods. New production processes and technical advances, the human genome project, for example, are contributing further to this development. In the next few years, an annual growth of about 15 per cent is predicted for biopharmaceuticals, while the growth rate for conventional pharmaceutical products is expected to be only about five per cent. However, this increase also means that attention must be paid to the biologically contaminated waste water generated by these processes. This article presents the state-of-the-art decontamination process technology and describes the advantages offered by systems in which all stages – from the production of ultra-pure water to the disposal of the waste water – are supplied by a single manufacturer.

SPECIFIC PROBLEMS IN THE MANUFACTURE OF BIOPHARMACEUTICALS

Biopharmaceuticals are manufactured by fermentation with microorganisms or viruses. The production methods for such products thus differ greatly from those used for conventional pharmaceuticals. If, for example, a plant produces vaccines, the waste water from the fermentation stage must be examined and treated very carefully.

Depending on the biological safety class (BL 1, BL 2 or BL 3), all waste water from a biotechnological production system must be treated – in general, this means sterilised – such that no microorganisms can enter the factory’s waste-water treatment plant and that there is absolutely no potential contamination hazard for the environment. This decontamination of the waste water is generally carried out with a batch-mode or continuous sterilisation system.

The waste water frequently contains a mixture of fermentation residues, as well as microorganisms and the water used for flushing and CIP. Its composition may vary widely and it may also contain solid particles. The treatment systems must therefore be very robust and designed to be extremely safe. The treatment of biological waste water is thus a key function of a biotechnological production system.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Helmut Sommer, Sales Manager at Christ AG, graduated with a degree in Mechanical Engineering from the Polytechnic Institute of Braunschweig, Germany. After this he worked in digital imaging processing and automation systems at Mc Cune & Stewart as a Project Engineer and Technical Manager. Helmut then worked at Pharmaplan and Pharmatec in Bad Homburg and Dresden, planning and developing water plants, in particular WFI and ultrapure steam generators. He has been at Christ AG, Switzerland, since 2003, as a Sales Manager for pharmaceutical plants, and is responsible for the further development of Multitron and Vapotron.
spacer
Helmut Sommer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement